- Home
- CGTL vs TNXP Comparison
CGTL vs TNXP Comparison
Compare CGTL & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGTL
- TNXP
- Stock Information
- Founded
- CGTL 2016
- TNXP 2007
- Country
- CGTL Hong Kong
- TNXP United States
- Employees
- CGTL N/A
- TNXP N/A
- Industry
- CGTL
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- CGTL
- TNXP Health Care
- Exchange
- CGTL NYSE
- TNXP Nasdaq
- Market Cap
- CGTL 70.3M
- TNXP 71.6M
- IPO Year
- CGTL 2024
- TNXP N/A
- Fundamental
- Price
- CGTL $4.30
- TNXP $18.18
- Analyst Decision
- CGTL
- TNXP Strong Buy
- Analyst Count
- CGTL 0
- TNXP 2
- Target Price
- CGTL N/A
- TNXP $585.00
- AVG Volume (30 Days)
- CGTL 65.4K
- TNXP 2.6M
- Earning Date
- CGTL 05-15-2025
- TNXP 03-18-2025
- Dividend Yield
- CGTL N/A
- TNXP N/A
- EPS Growth
- CGTL 35.72
- TNXP N/A
- EPS
- CGTL 0.21
- TNXP N/A
- Revenue
- CGTL $35,611,761.00
- TNXP $10,094,000.00
- Revenue This Year
- CGTL N/A
- TNXP $84.08
- Revenue Next Year
- CGTL N/A
- TNXP $126.94
- P/E Ratio
- CGTL $19.71
- TNXP N/A
- Revenue Growth
- CGTL N/A
- TNXP 29.94
- 52 Week Low
- CGTL $2.80
- TNXP $6.76
- 52 Week High
- CGTL $10.59
- TNXP $672.00
- Technical
- Relative Strength Index (RSI)
- CGTL N/A
- TNXP 48.95
- Support Level
- CGTL N/A
- TNXP $12.80
- Resistance Level
- CGTL N/A
- TNXP $31.87
- Average True Range (ATR)
- CGTL 0.00
- TNXP 4.30
- MACD
- CGTL 0.00
- TNXP 0.57
- Stochastic Oscillator
- CGTL 0.00
- TNXP 22.53
About CGTL CREATIVE GLOBAL TECHNOLOGY HOLDINGS LIMITED
Creative Global Technology Holdings Ltd conducts its business through its subsidiary, which is a Hong Kong-based company sourcing and reselling recycled consumer electronic devices, currently mostly smartphones, tablets, and laptops.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.